Overview

Learners will gain insights into the distinct features of acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL), including their cell of origin, immunophenotypic markers, cytogenetic abnormalities, clinical presentation, and prognosis. Case scenarios will be used to illustrate the differences between AML and ALL.  Various treatment modalities used for both AML and ALL, including chemotherapy, targeted therapy, immunotherapy, hematopoietic stem cell transplantation (HSCT), and supportive care interventions will be discussed. The rationale behind treatment selection and multidisciplinary approaches will also be emphasized.

Target Audience

This CME initiative was designed for oncologists, surgeons, radiation oncologists, NPs, PAs, pharmacists, nurses, and other healthcare professionals involved in the treatment of patients with cancer.

Learning Objectives

1. Define acute leukemia and distinguish its characteristics
2. Recognize the risk factors associated with the development of acute leukemia
3. Differentiate between acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL), focusing on their distinct features
4. Discuss the treatment modalities utilized for both AML and ALL
5. Identify common side effects of AML and ALL treatments and develop strategies for their management